JAMA Oncology Acceptance Rate

The open citation trend is up from 7.62 in 2023 to 8.32 in 2024. That does not directly change the acceptance rate, but it supports the more practical point: JAMA Oncology remains a high-attention journal that can afford to be selective.

The older answer on this query was that JAMA Oncology did not publish a stable official rate. That is no longer the best answer. In March 2026, the journal's year-in-review editorial reported 8% overall acceptance in 2025 and 4% acceptance for research papers.

What is more stable than any one percentage is the editorial context:

• JAMA Oncology is part of the JAMA Network, with the JAMA editorial standards and review process
• the journal emphasizes clinical oncology with broad consequence
• receipt to first decision with peer review was 33 days in the 2025 year-in-review report
• clinical trials, population-level analyses, and guideline-relevant studies are prioritized

That clinical-evidence focus and JAMA Network editorial rigor define the real submission bar.

At triage, the editor is usually asking:

• does this study change how oncologists will treat, screen, or monitor patients?
• is the evidence clinical-level, such as randomized trials, large cohorts, systematic reviews, or registry analyses?
• does the study design meet JAMA Network standards for statistical rigor and reporting?
• would the findings inform clinical guidelines or broad oncology practice?

Papers with large, well-designed clinical trials or population-level evidence survive triage at much higher rates than small translational studies or single-center observations.

In our pre-submission review work evaluating manuscripts targeting JAMA Oncology, three failure modes account for most desk rejections.

Translational cancer study submitted as clinical oncology. The manuscript may use patient material, but the scientific contribution is still mostly biological mechanism rather than patient-management evidence.

Small clinical study without the scale for practice-changing conclusions. Single-center outcome series and modest retrospective cohorts can be rigorous and still fall below the journal's evidence threshold.

Clinical study failing JAMA statistical reporting standards. We often see missing pre-specified endpoints, weak handling of multiplicity, thin confidence-interval reporting, or incomplete trial-reporting discipline.

The acceptance rate is useful context. The better operational question is whether the paper already looks like broad clinical-oncology evidence on first read.

For JAMA Oncology, the useful question is:

Does this study provide clinical oncology evidence strong enough to change practice or inform guidelines?

If yes, the journal is a strong fit. If the paper is primarily translational, primarily basic science, or a small clinical study without population-level implications, the acceptance rate is not the constraint. The evidence level is.

The common misses are:

• centering strategy around a percentage instead of checking clinical evidence level
• submitting translational work without a strong clinical bridge
• presenting single-center data without population-level generalizability
• underestimating JAMA Network reporting and statistical standards
• ignoring JCO as the primary competitor for the same manuscript pool

Those are evidence-level and scope problems before they are rate problems.